PMID- 27860123
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20170807
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Linking)
VI  - 19
IP  - 1
DP  - 2017 Feb
TI  - Cytomegalovirus and cancer after kidney transplantation: Role of the human 
      leukocyte antigen system?
LID - 10.1111/tid.12631 [doi]
AB  - BACKGROUND: The role of cytomegalovirus (CMV) in cancer development after 
      transplantation remains uncertain. We aimed to determine the association between 
      donor and recipient CMV serological status and the risk of cancer development 
      after kidney transplantation. METHODS: Using data from the Australian and New 
      Zealand Dialysis and Transplant (ANZDATA) Registry, we assessed the association 
      between CMV donor/recipient (D/R) serological status and the risk of solid organ 
      cancers in primary adult deceased-donor kidney transplant patients between 1990 
      and 2012. RESULTS: Of 8140 recipients, a total of 895 (11%) recipients developed 
      incident cancers during a follow-up time of 51 555 person-years. Human leukocyte 
      antigen (HLA) mismatches was an effect modifier between CMV serological status 
      and cancer (P=.03 for interaction). In recipients who have received 0-2 HLA-ABDR 
      mismatched kidneys, the adjusted hazard ratios for cancer incidence among those 
      with CMV D-/R-, CMV D-/R+, and CMV D+/R- were 0.47 (95% confidence interval [CI]: 
      0.24-0.91), 1.42 (95% CI: 0.97-2.07), and 1.02 (95% CI: 0.67-1.57), respectively 
      compared with the reference of CMV D+/R+. A similar association was not observed 
      in those with >2 HLA-ABDR mismatches. CONCLUSION: CMV D-/R- status was associated 
      with a reduced risk of cancer in kidney transplant recipients who have received 
      well-matched renal allografts, suggesting a potential role of HLA matching in 
      cancer development.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Wong, Germaine
AU  - Wong G
AD  - Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
AD  - Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, 
      Australia.
FAU - Chakera, Aron
AU  - Chakera A
AD  - Renal Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia 
      School of Medicine and Pharmacology, University of Western Australia, Western 
      Australia Harry Perkins Institute of Medical Research, Verdun St. Nedlands, WA, 
      Australia.
FAU - Chapman, Jeremy R
AU  - Chapman JR
AD  - Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, 
      Australia.
FAU - Chadban, Steve C
AU  - Chadban SC
AD  - Central Clinical School, Royal Prince Alfred Hospital, University of Sydney, 
      Sydney, NSW, Australia.
FAU - Pilmore, Helen
AU  - Pilmore H
AD  - Department of Renal Medicine, Auckland City Hospital and Department of Medicine, 
      Auckland University, Auckland, New Zealand.
FAU - Craig, Jonathan C
AU  - Craig JC
AD  - Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
FAU - Lim, Wai H
AU  - Lim WH
AD  - Renal Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia 
      School of Medicine and Pharmacology, University of Western Australia, Western 
      Australia Harry Perkins Institute of Medical Research, Verdun St. Nedlands, WA, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20161229
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation 
      Society
JID - 100883688
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia/epidemiology
MH  - Cytomegalovirus/*isolation & purification
MH  - Cytomegalovirus Infections/*complications/epidemiology/*immunology/virology
MH  - Female
MH  - Follow-Up Studies
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Incidence
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*complications/epidemiology/*immunology
MH  - New Zealand/epidemiology
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Serologic Tests
MH  - Transplantation, Homologous/adverse effects
OTO - NOTNLM
OT  - HLA
OT  - cancer
OT  - cytomegalovirus
OT  - epidemiology
OT  - kidney transplantation
OT  - outcomes
EDAT- 2016/11/20 06:00
MHDA- 2017/08/08 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/04/17 00:00 [received]
PHST- 2016/07/11 00:00 [revised]
PHST- 2016/08/01 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - 10.1111/tid.12631 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12631. Epub 2016 Dec 29.